Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report
Year: 2026
Type: article
Study design: Case Report
Abstract: Background EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective treatments for EGFR-mutant advanced non-small cell lung cancer, but drug-induced interstitial lung disease (ILD) can interrupt treatment. Resuming EGFR inhibition after ILD presents a difficult decision when chemotherapy is poorly tolerated. Case presentation A 69-year-old woman with stage IVB lung adenocarcinoma harboring an EGFR exon 21 L858R mutation and EGFR amplification discontinued chemotherapy after one cycle because of gastrointestinal intolerance. Almonertinib produced a partial response in the primary lung lesion and brain metastases. After approximately 3 months, she developed cough, chest tightness, hypoxemia, and bilateral pulmonary infiltrates. Evaluation for infection, autoimmune disease, cardiac dysfunction, and tumor progression supported almonertinib-induced ILD. Bronchoalveolar lavage showed 89.0% lymphocytes, with negative pathogen testing. Almonertinib was discontinued, and systemic corticosteroids led to clinical and radiological improvement. Following multidisciplinary review and informed consent, furmonertinib 80 mg once daily was started on November 15, 2025, while she was taking oral methylprednisolone 16 mg daily. The methylprednisolone dose was gradually tapered. Corticosteroids were discontinued on February 15, 2026. At the last follow-up on April 18, 2026, approximately 5 months after initiation of furmonertinib, systemic and intracranial disease remained controlled, with no recurrence or worsening of ILD. Conclusion This case documents resumption of EGFR inhibition with an alternative third-generation EGFR-TKI after improvement of almonertinib-induced ILD. Clinical and radiological recovery, prior tumor response, available treatment alternatives, patient preference, and close monitoring informed the decision.
Source: Frontiers in Oncology
Authors: Qingsen Gao(Data curation, Writing – original draft), Dongxing Yang(Data curation, Writing – original draft), Jia Wang(Data curation, Formal analysis, Writing – review & editing), Chenxi Wei(Conceptualization, Data curation, Project administration, Writing – review & editing), Lisha Zhang(Project administration, Writing – review & editing)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: furmonertinib, almonertinib, drug-induced interstitial lung disease, EGFR tyrosine kinase inhibitors, EGFR-mutant lung adenocarcinoma, EGFR exon 21 L858R mutation, EGFR amplification, third-generation EGFR-TKI, drug rechallenge, corticosteroid therapy, brain metastases, non-small cell lung cancer
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236083517
